GW&K Investment Management LLC Increases Position in Charles River Laboratories International, Inc. $CRL

GW&K Investment Management LLC boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 96,654 shares of the medical research company’s stock after acquiring an additional 8,341 shares during the period. GW&K Investment Management LLC owned about 0.20% of Charles River Laboratories International worth $15,122,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its holdings in shares of Charles River Laboratories International by 11.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock worth $124,000 after acquiring an additional 80 shares during the period. Rothschild Investment LLC increased its stake in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Charles River Laboratories International by 4.2% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company’s stock worth $332,000 after purchasing an additional 85 shares during the period. Resona Asset Management Co. Ltd. raised its holdings in shares of Charles River Laboratories International by 17.5% in the 3rd quarter. Resona Asset Management Co. Ltd. now owns 584 shares of the medical research company’s stock worth $86,000 after purchasing an additional 87 shares during the period. Finally, WESCAP Management Group Inc. lifted its stake in shares of Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 89 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRL has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Mizuho reduced their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a report on Friday, February 20th. Wall Street Zen cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Barclays cut their price objective on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, February 19th. Finally, Citigroup boosted their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Trading Down 3.4%

NYSE:CRL opened at $175.08 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $228.88. The stock has a market cap of $8.62 billion, a price-to-earnings ratio of -59.15, a PEG ratio of 3.10 and a beta of 1.64. The business has a fifty day moving average of $195.31 and a 200-day moving average of $180.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. During the same period in the previous year, the firm earned $2.66 EPS. The business’s revenue for the quarter was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.